Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Medical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12032-014-0404-yPMID 25471787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.

  2014cited by this paper
• Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer

  2014cited by this paper
• A survey and evaluation of population-based screening for gastric cancer

  2013cited by this paper
• STAT3 is associated with lymph node metastasis in gastric cancer

  2013cited by this paper
• Determinants of the extent and duration of STAT3 signaling

  2012cited by this paper
• Correlation of Epigenetic Aberrance with STAT3 Signaling Pathway in Gastric Carcinogenesis

  2012cited by this paper
• Correlation of Epigenetic Aberrance with STAT3 Signaling Pathway in Gastric Carcinogenesis

  2012cited by this paper
• High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.

  2012cited by this paper
• Comparative epidemiology of gastric cancer between Japan and China.

  2011cited by this paper
• STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer.

  2010cited by this paper
• STATs in cancer inflammation and immunity: a leading role for STAT3

  2009cited by this paper
• STAT3 expression in gastric cancer indicates a poor prognosis

  2009cited by this paper
• Requirement of Histone Methyltransferase SMYD3 for Estrogen Receptor-mediated Transcription*

  2009cited by this paper
• Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells

  2009cited by this paper
• Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro.

  2008cited by this paper
• Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.

  2007cited by this paper
• Phospho‐Stat3 expression and correlation with VEGF, p53, and Bcl‐2 in gastric carcinoma using tissue microarray

  2006cited by this paper
• Enhanced SMYD3 expression is essential for the growth of breast cancer cells

  2006cited by this paper
• Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival.

  2006cited by this paper
• Expression of Activated Signal Transducer and Activator of Transcription 3 Predicts Expression of Vascular Endothelial Growth Factor in and Angiogenic Phenotype of Human Gastric Cancer

  2005cited by this paper
• SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells

  2004cited by this paper
• Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.

  2003cited by this paper
• Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

  2002cited by this paper
• Risk factors predictive of lymph node metastasis in depressed early gastric cancer.

  2002cited by this paper
• STAT proteins: novel molecular targets for cancer drug discovery

  2000cited by this paper

• The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance

  2024cites this paper
• Histone and DNA Methylation as Epigenetic Regulators of DNA Damage Repair in Gastric Cancer and Emerging Therapeutic Opportunities

  2023cites this paper
• MicroRNA-155 and cancer metastasis: Regulation of invasion, migration, and epithelial-to-mesenchymal transition.

  2023cites this paper
• Emerging Role of SMYD Family of Proteins in Human Tumorigenesis

  2023cites this paper
• SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation

  2022cites this paper
• Clinical prognostic value of the SMYD2/3 as new epigenetic biomarkers in solid cancer patients: a systematic review and meta-analysis

  2022cites this paper
• OSgc: A Web Portal to Assess the Performance of Prognostic Biomarkers in Gastric Cancer

  2022cites this paper
• Overexpression of SMYD3 contributes to sorafenib resistance by epigenetically activating the expression of multiple cancer-promoting genes in hepatocellular carcinoma

  2021cites this paper
• Identification of potential pathways whereby dietary L-tryptophan ameliorates the glucose metabolic disorder of blunt snout bream through long non-coding RNAs

  2021cites this paper
• Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies

  2021cites this paper
• Comprehensive Analysis of the Value of SMYD Family Members in the Prognosis and Immune Infiltration of Malignant Digestive System Tumors

  2021cites this paper
• Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening

  2021cites this paper
• SMYD3: a regulator of epigenetic and signaling pathways in cancer

  2021influential citation
• Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora

  2020cites this paper
• Roles of Histone Modifications in Gastrointestinal Tumorigenesis

  2020cites this paper
• SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non-small cell lung cancer

  2020cites this paper
• Lysine Methyltransferases Signaling: Histones are Just the Tip of the Iceberg.

  2020cites this paper
• Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma

  2020cites this paper
• Leitlinienreport zur S3-Leitlinie Magenkarzinom – „Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs“

  2019cites this paper
• STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo

  2019cites this paper
• Is MYND Domain-Mediated Assembly of SMYD3 Complexes Involved in Calcium Dependent Signaling?

  2019cites this paper
• Regulation of miR-155 affects the invasion and migration of gastric carcinoma cells by modulating the STAT3 signaling pathway

  2018cites this paper
• SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells

  2018cites this paper
• STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression

  2018cites this paper
• SET and MYND domain containing protein 3 in cancer.

  2017cites this paper
• Methylation modification in gastric cancer and approaches to targeted epigenetic therapy (Review).

  2017cites this paper
• Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents

  2017cites this paper
• Prognostic significance of stromal SMYD3 expression in colorectal cancer of TNM stage I-III.

  2017cites this paper
• Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

  2016cites this paper
• Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients

  2016cites this paper
• Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy

  2016cites this paper
• Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer

  2015cites this paper
• SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.

  2015cites this paper
• Abstract C85: Identification of a novel potent selective SMYD3 inhibitor with oral bioavailability

  2015cites this paper
• Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-β1 in Gastric Cancer.

  2015cites this paper